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Abstract
Background: Rubella is an acute infectious disease caused by Rubella virus (RUBV). RUBV remains an important
pathogen worldwide, causing approximately 100 000 cases of congenital rubella syndrome (CRS) every year; and
the most severe consequence of rubella is teratogenicity. The aim of this study was to estimate the prevalence of
RUBV IgG antibodies and determine RUBV genotypes in Congolese pregnant women in Kongo central province,
Democratic Republic of Congo (DRC).
Methods: This was a prospective cross-sectional study that consisted of a laboratory analysis of blood samples
from 78 pregnant women to check for the presence of RUBV IgG antibodies, and also determine RUBV genotypes
in seropositive samples (using primers targeting RUBV nucleoprotein), with the use of serological and molecular
methods, respectively. Participants were pregnant women attending antenatal care clinics (ANC) at two health
zones of Kisantu town in DRC. They were followed-up from the first to third trimester. Those who were negative
for RUBV antibodies at the initial assay (first trimester) were tested in the second and, eventually, the third trimester.
Results: An overall rubella seroprevalence of 58.97% was observed, whereas RUBV nucleoprotein was detected in
60% of randomly selected 30 blood samples among the 46 RUBV seropositive pregnant women. Five (27.77%) of
positive samples were positive for both RUBV genotypes (RV8633/9112 and RV8945/9577), whereas 11 (61.11%) of
them were positive for RV8633/9112 and two (11.11%) were positive for RV8945/9577 only. Regarding rubella
clinical signs and complications, two subjects (2.56%) presented with fever, whereas five pregnant women (6.41%)
had experienced abortion. None (0%) of the participants has been vaccinated against RUBV.
Conclusions: Findings from this study suggest that RUBV is prevalent in Congolese pregnant women. Further
research is required to elucidate the molecular epidemiology of RUBV in order to design a rational rubella
surveillance and control program in DRC.
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Background
Rubella is an acute infectious disease that normally has a
mild clinical course, caused by rubella virus (RUBV).
RUBV remains an important pathogen worldwide, caus-
ing approximately 100 000 cases of congenital rubella
syndrome every year [1, 2]. RUBV is classified into the
family Togaviridae. The virus is roughly spherical with a
diameter of 60-70 nm. Togaviridae family contains two
genera, the Alphaviruses and the Rubivirus, RUBV being
the sole member of the Rubivirus genus. The positive
sense genome of RUBV consists of approximately 10,000
nucleotides and has one open reading frame (ORF) en-
coding the nonstructural proteins (NSPs) and one ORF
for a subgenomic RNA encoding the structural proteins
[3]. In the most recent WHO update, the standard no-
menclature for the classification and designation of wild-
type RUBV strains recognizes nine definitive and four
provisional genotypes [4] expanding the nomenclature
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established in 2005 which was based on 739 nucleotides
(nt) (nt 8731 to 9469) from the E1 gene sequence. This
sequence encodes amino acids (aa) 159 to 404 (of the
481 aa) of the E1 glycoprotein. Although the knowledge
of the geographic distribution of RUBV genotypes has
grown substantially since 2003, the genotypes present in
many countries and regions remain unknown [5], even
though rubella is still recognized as a global public
health issue [6].
The clinical manifestations of Rubella include a mild ex-
anthema that is frequently accompanied by adenopathy
and, occasionally, arthralgia. It can cause fetal death or
congenital rubella syndrome (CRS) during early pregnancy
(first trimester) which is characterized by multiple defects
to the brain, heart, eyes and ears [1]. Encephalopathy and
thrombocytopenia are rare complications of the disease.
Itsmost severe consequence teratogenicity. This causes
high neonatal morbidity and serious burden to families [7,
8].
Rubella has almost been eradicated by immunization
programs in many developed countries, but outbreaks
among unvaccinated individuals still occur [9]. The
infection also continues to circulate in many countries
with less effective immunization programs [10]. In some
African countries, rubella seropositivity of 71-99% has
been found in previous studies among women in their
reproductive age, with countries like Mozambique (95%)
andSouth Africa (97.5-98%) having highest incidence
[11–13]. In 2011, a measles surveillance campaign im-
plemented in the capital Kinshasa, Democratic Republic
of Congo (DRC), showed that 24% of blood samples
screened for measles were positive for rubella IgM anti-
bodies [14].
Despite the severe consequences of rubella infection
during early pregnancy, very little is known about the
rubella seroprevalence in a number of African coun-
tries, DRC in particular. There is, therefore, a contin-
ued demand for the assessment of pregnant women
who develop or have contact with rubella-like illnesses.
The diagnosis of rubella is currently made by using
serological techniques, and the risk to the fetus is
assessed by establishing the gestational age at the time
of maternal infection. Considering the negative health
consequences of RUBV on the fetus and offspring of in-
fected mothers, an early laboratory diagnosis of recent
or congenital infection through direct detection of
RUBV ribonucleic acid (RNA) in clinical specimens, in
addition to the detection of RUBV-specific immunoglo-
bin M (IgM), is obviously critical [15].
The World Health Organization (WHO) aims to elim-
inate measles and rubella and to reduce the incidence of
CRS to less than one case per 100,000 live births [16].
For this purpose, epidemiological surveillance based on
the laboratory diagnosis and the characterization of the
genotype of circulating strains are included in the
WHO’s recommendations. Between 2001 and 2008, a
WHO initiative against rubella has provided support to
developing countries including the DRC. However, this
initiative experienced non-continuity due to lower in-
vestment and the lack of political resolve that has led to
inadequate vaccination coverage in DRC for a number
of years.
To our knowledge, there have been no studies that
prospectively investigated rubella seroprevalence and
performed the molecular detection of circulating RUBV
strains among Congolese women attending antenatal
care (ANC) clinics. The aim of the present study was to
prospectively estimate rubella seroprevalence and deter-
mine RUBV genotypes among Congolese pregnant
women in Kisantu town, Kongo central province, DRC.
Methods
Study design, sites and participants
This was a prospective cross-sectional study that con-
sisted of a laboratory analysis of blood samples from
pregnant women undergoing antenatal care (ANC)
(N1 = 78) to check for the presence of rubella virus IgG
antibodies and also RUBV genotypes in RUBV seroposi-
tive subjects, with the use of serological and molecular
methods, respectively. DRC is a country located in the
African Great Lakes region. It is the second largest coun-
try in Africa with an estimated population of over 75
million [17]. This study was conducted in the Congolese
town of Kisantu, Kongo central province (formerly
Bas-Congo), from 1 February through March 2014.
Kisantu is located approximately at 110-115 Km from
the capital Kinshasa. According to the current Congolese
health system, Kisantu is divided into four ‘health zones’,
including Nkandu, Kikonka, Kintanu 1 and Kintanu 2.
Each health zones comprises one or more health centers.
The present study was conducted at the antenatal care
clinics (ANC) of Kintanu 1 and 2 health centers (Fig. 1).
A consecutive sampling technique was applied in the
population of pregnant women visiting ANC clinics in
selected study sites. Participants were interviewed and
the information obtained was recorded in an epidemio-
logical form. They also provided blood samples for sero-
logical analysis, and a randomly selected sample of blood
specimens from RUBV seropositive pregnant women was
used to determine RUBV genotypes.
Procedures
Detection of IgG anti-rubella
Blood samples were collected from pregnant woman at-
tending ANC in Kisantu. After collection, blood samples
were transported on ice in cold boxes to the Saint Luc
laboratory in Kisantu for the serodiagnosis of rubella
virus infection. Blood samples were allowed to clot and
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centrifuged for serum separation prior to testing. All
sera were stored at −20 °C until use. Evidence of pres-
ence rubella contamination was tested using an IgG
enzyme-linked immunoassay to detect rubella-specific
IgG antibodies, according to the manufacturer’s specifi-
cations (Wampole Laboratories, Cranbury, New Jersey,
United States of America USA). The limit of detection
of the test was 6.2 IU/mL. Individuals with an IgG titer
>8.6 IU/mL were defined as seropositive, whereas titers
between 6.2–8.6 IU/mL were classified as borderline.
Molecular analysis
Before clotting, blood samples were spotted onto FTA
cards for molecular analysis. FTA cards were allowed to
dry and stored at room temperature before they were
transported to SUA for RUBV detection using RT-PCR.
a) RNA extraction
A sterile scapel blade was used to remove 25 mm
discs from the center of each dried sample spot on the
FTA Card. Viral RNA was recovered from sera using
QIAamp Viral RNA Mini extraction kit (Qiagen,
Hilden, Germany), according to the manufacturer’s in-
structions (Appendix 2). Briefly, samples were lysed
using a lysis buffer to lyse cells and viral envelope
followed with chemical protein precipitation using
ethanol. Protein precipitates were pelleted by centrifu-
gationand the supernatant was passed through a silica
column to trap the RNA.Column-bound RNA were
washed with two different buffers and the column
dried by high speed centrifugation. Afterwards,
column-bound RNA was eluted with RNase free
water. Extracted viral RNA was stored at −80 °C until
RT-PCR.
b) Reverse transcription polymerase chain reaction (RT-
PCR) for the detection of RUBV
RT-PCR for the detection of RUBV was carried out in
a GeneAmp PCR system 9700 (Applied Biosystems,
Carlsbad, USA) using AgPath-ID one-step RT-PCR kit
(Applied Biosystems, Courtaboeuf, France). The RT-PCR
master mix for a single reaction is shown in Table 1.
Briefly, reverse transcription was performed using a re-
verse transcriptase for 30 min at 50 °C followed by initial
denaturation of DNA for 15 min at 95 °C. Afterwards,
40 PCR cycles consisting of denaturation of DNA at 94 °C
for 30 s, annealing of primers at 55 °C for 30 s and DNA
extension by a DNA polymerase for 60 s. PCR was
followed by a final extension at 72 °C for 10 min. Partial
RUBV amplification was performed using either RUBV
Fig. 1 Map of Kisantu showing health settings within Kisantu town and the 2 study sites, Kintanu1 and Kintanu2 (Courtesy of Central Bureau of
Kisantu health zone, Kongo central, Democratic Republic of Congo)
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primer pair RV 8633 and RV 8945 or RV 9112 and RV
9577.
RT-PCR products were separated by electrophoresis
on a 1·5% agarose gel in 0·5%TBE buffer (SERVA Elec-
trophoresis, Heidelberg, Germany) stained with GelRed
nucleic acid stain (Phenix Research Products, Candler,
USA). Each well was loaded with 5 μl of the PCR prod-
uct and 3 μl of blue / orange 6X DNA loading dye (Pro-
mega, Madison, USA). Samples were separated along
with a 1000 bp DNA ladder (Promega, Madison, USA)
at 150 V for 30 min. The agarose gel was visualized
using a gel documentation system (EZ gel doc BioRad,
France).
Ethical consideration and data analysis
The study protocol was approved by the ethics commit-
tee of Sokoine University, Tanzania, and a written
authorization was obtained from the Kisantu area health
authority. Informed consent was obtained from each
participant; those who did not consent were excluded
from the study, but none of them was penalized. Quali-
tative data are presented as proportions. Fisher’s exact
test was performed to assess the relationship between
any two categorical variables, whereas logistic regression
test was used to assess the correlation between rubella
seropositivity and participants’ characteristics. The ana-
lyses were performed using Epi info version 7 software.
For the different statistic tests (bivariate analysis), the
level of significance was set at 5% (2- tailed p).
Results
Socio-demographic characteristics of participants (Table 2)
In the present study, a total of seventy eight pregnant
women were enrolled after obtaining their consent. The
enrolled pregnant women were aged 14-43 years with a
median age of 25 years; 30.77% (24/78) of women were
primigravidea. The majority (75.64%; 59/78) of the en-
rolled subjects were married, whereas only 24.36% (19/
78) subjects were single. The education level differed
among subjects including university education (6.41%; 5/
78) and high school education (78.21%; 61/78). Most
pregnant women enrolled in this study were from
Kintanu 2; the group of those who were in their first
trimester of gestational age comprised 11 subjects
(14.10%). None of the pregnant women enrolled in this
study has been vaccinated against rubella.
Rubella clinical signs and seroprevalence of RUBV
antibodies
Table 3 shows the relationship between rubella seroposi-
tivity and the sociodemographic and obstetrical charac-
teristics of the study participants, namely age, marital
status, occupation, parity/gravidity and gestational age.
No association was found between the serological status
of the pregnant women with either of the participants’
characteristics (Table 3).
Regarding rubella clinical signs or complications in the
study participants, fever was observed in two subjects
(2.56%), whereas five pregnant women (6.41%) had expe-
rienced abortion. Non-specific rubella signs were found
in 10.26% (8/78) of participants. On the other hand, of
the 78 serum samples from the study participants that
were tested for the presence of RUBV antibodies, the
seroprevalence of rubella IgG antibodies was 58.97%
(46/78) (Fig. 2).
Confirmation of RUBV by RT-PCR
A total of 30 samples were randomly selected and tested
for RUBV using RT-PCR. RUBV was detected in 18 out
of 30 samples (60%) (Fig. 3). Of the 18 positive samples,
eight (44.44%) were from Kintanu 1 and ten (55.55%)
from Kintanu 2. Regarding RUBV genotypes, of the 18
positive samples, 11 (61.11%) were positive when the
primer pair RV 8633/9112 was used, whereas two
(11.11%) were positive using the RV 8945/9577 primer
Table 1 Reverse transcription polymerase chain reaction
(RT-PCR) master mix components for a single reaction carried
out using AgPath-ID one–step RT-PCR kit from Applied Biosystems
to detect RUBV in FTA cards
No Component Volume (mL)
1 2 X RT-PCR Buffer 12▪5
2 10 ΜM RV8633 or RV9112 1
3 10 ΜM RV8945 or RV9577 1
4 Nuclease-free water 9
5 25XRT-PCR Enzyme Mix 0.5
6 Extracted DNA template 1
Total volume per reaction 25▪0
Table 2 Socio-demographic and obstetrical characteristics of
participants
Sociodemographics n (%)
Age < 30 y. 58 (74▪36)
30 - 43 y. 20 (25▪64)
Parity Primigravid 24 (30▪77)
Multigravid 54 (69▪23)
Gest. age 1st Trimester 11 (14▪10)
2nd & 3rd Trimester 67 (85▪90)
Marital status Single 19 (24▪36)
Married 59 (75▪64)
Occupation Presence of activity 47 (60▪26)
Housewife 31 (39▪05)
Residence Kintanu 1 25 (32▪05)
Kintanu 2 53 (67▪95)
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pair. In addition, five samples (27.77%) were positive on
both RV 8633/9112 and RV8945/9577 primer pairs.
Discussion
This study determined the seroprevalence of rubella
among Congolese pregnant women attending ANC in
Kisantu town, DRC, with the use of serological and mo-
lecular methods. Antibodies (IgG) against RUBVwere
detected using ELISA, whereas RUBV genome was de-
tected using RT-PCR. The findings showed that more
than half (58.97%) of pregnant women were seroposi-
tive for rubella virus. This seroprevalence is similar to
results from two other studies carried out in Sudan and
Nigeria, which showed a seroprevalence of 65-68%, re-
spectively [18–21]. On the other hand, studies con-
ducted in Burkinafaso, Senegal and Iran showed higher
rubella seroprevalence (95.0, 90.1 and 96.2%, respect-
ively) among pregnant women [22, 23]. Another study
conducted among urban and rural pregnant women in
Namibia showed an overall rubella seroprevalence of
85%, with urban women having higher risk of infection
[24]. These differences in seroprevalence rates can be
attributed to the degree of contamination at national
level, the testing method used and/or the size of the
sample used.
Since rubella vaccine is rarely given to adults in DRC,
our results suggest that a sizable number of women be-
come infected during child-bearing age. The mostex-
posed age group being between 14 to 29 years of age.
According to a study conducted in Cameroon in 2011,
the age group of women from 20 to 39 was considered
to have a maximum fertility [25]. Our findings highlight
the need for the country to establish surveillance of
trends in susceptibility to rubella and CRS incidence and
introduce of rubella vaccination among women of child-
bearing age.
Our study also showed that neither age, gestational age,
gravidity, marital status nor occupation was significantly
associated with presence of RUBV IgG. Studies conducted
in Burkinafaso and Sudan also showed no correlations
between rates of rubella seropositivity and educational,
marital, and pregnancy status, monthly income or history
Table 3 Correlation between rubella and characteristics of study participants
Sociodemographic and obstetrical
characteristics
Rubella IgG positive OR 95% Cl P-value
n (%)
Age <30 36 1▪23 0▪34 - 4▪45 0▪99
30-43 10 - -
Parity/gravidity Primigravid 16 - -
Multigravid 30 0▪62 0▪22 - 1▪70 0▪51
Gestational age Trimester 1 6 - -
Trimester 2&3 40 1▪23 0▪34 - 4▪45 0▪99
Marital status Single 13 - -
Married 33 0▪58 0▪19 - 1▪70 0▪48
Occupation Presence of job 26 0▪59 0▪22 - 1▪52 0▪39
Housewife 20 - -
Fig. 2 Clinical signs, complications and rubella seroprevalence among participants
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of previous exanthematous diseases [18, 23]. This lack
ofrelationship seems toaffectall studiesdespitethe size of
thesample, the location ofthe studyorthevariationof gesta-
tional age. Nevertheless, the overall results indicate that a
considerable proportion of pregnant women in DRC are
at risk of primary infection with rubella virus.
Widespread use of rubella vaccine in most developed
countries has contributed to markedly reducing rubella
incidence. Since the 1970’s, in many of those countries,
vaccination programmes have been targeting pre-
adolescent girls before they become sexually active [19].
In contrast, in several countries of the developing
world, rubella immunization programme does not exist.
Of the 46 African countries covered by the WHO mea-
sles prevention programme, only two countries, namely
Mauritius and Seychelles, have included routine rubella
vaccine in their national vaccination programmes [13,
20]. Our study showed that none of the participating
pregnant women has been immunized against rubella.
This confirms that rubella vaccination is not part of ac-
tivities included in ANC clinics in DRC, and particu-
larly in Kongo central province where the study was
conducted.
Limitations and strengths
This study has some limitations. The sample was rela-
tively low, 78 pregnant women. This was a study in
which participants were enrolled prospectively, and ac-
cording to our study protocol, we expected a least 100
pregnant women undergoing ANC would be enrolled
within the 2-month period of the study, given the rela-
tively high natality rate in DRC. However, a number of
factors might have affected pregnant women’s willing-
ness to participate in this study. Firstly, participation was
voluntary and only those who freely accepted to take
part and accepted to undergo blood sampling and test-
ing were eligible. It is well known that in rural Congo, as
well in most other areas in the Sub-Saharan African
countries, medical procedures such as vaccination and
blood sampling for reasons other than hospital-based
patient’s care face opposition from community members’
beliefs. Moreover, the sample size may have also been af-
fected by the accessibility to ANC in the context of pov-
erty in rural Kongo central (Bakongo) where this study
was carried out. In fact, ANC accessibility is limited as,
depending on household socioeconomic status, the
choice between health center and rural or village birth
attendant is decided.
Another fact is that, of the 78 blood samples, 30 ran-
domly selected samples were assayed to determine the
RUBV genotypes in study participants. RT-PCR was a
complementary assay performed not systematically for
all 78 participants but only for those who were positive
in the serological analysis (RUBV antibodies); thus, the
randomization concerned not 78 samples but 46 ‘RUBV
antibody’ positive samples, of which 30 were randomly
drawn for RT-PCR with the purpose of identifying
RUBV genotypes.
Nonetheless, this prospective study provides new
knowledge in regard to the trend of rubella seropreva-
lence among Congolese pregnant women and RUBV ge-
notypes circulating in the region. Thus, it may serve as a
reference for future research projects on rubella and,
eventually, the design of rubella surveillance and control
program of in DRC.
Conclusions
As a conclusion, the present study showedthat RUBV is
circulating widely in pregnant women in DRC and that
RUBV is present in Kisantu area in Bas Congo region.
The antibodies and genome of RUBV were detected by
ELISA (IgG) and RT-PCR. The results of the study also
confirm for the first time the presence of RUBV genome
in Kisantu, DRC. Based on these findings, it should be
recommended that serological and molecular screening
tools should be used in surveillance for RUBV in DRC,
especially in pregnant women in order to control rubella.
A high seropositivity in the absence of vaccination indi-
cates a high risk posed to newborns due to CRS. More
studies on the epidemiologyof RUBV are recommended
to gather more data for effective control measures in-
cluding characterizing the strains that can be used for
development of specific vaccine.
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